Key result
Ramipril, but not nifedipine or dihydralazine, prevented the development and induced complete regression of cardiac hypertrophy in rats with aortic banding, even at nonantihypertensive doses.
Why the study?
Does ramipril prevent or regress cardiac hypertrophy in rats with aortic banding compared to other antihypertensive agents?
Population
Rats subjected to banding of the abdominal aorta (hypertension and hypertrophy model)
Comparison
Ramipril vs Nifedipine, dihydralazine, untreated animals…
Design
Preclinical
Follow-up
6 weeks
Authors
Loading...
Findings in rats warrant no practice change; leaves open confirmation of ACE inhibition's BP-independent benefits in human cardiac hypertrophy.
Does ramipril prevent or regress cardiac hypertrophy in rats with aortic banding compared to other antihypertensive agents?
ACE inhibition with ramipril specifically prevents and regresses hypertensive cardiac hypertrophy in rats independent of its blood pressure-lowering effects, suggesting a direct role of angiotensin II in cardiac growth.
Linz et al. (1989) studied Cardiac hypertrophy and hypertension. Ramipril vs. Nifedipine (30 mg/kg), dihydralazine (30 mg/kg), untreated controls, and sham-operated controls was evaluated on Cardiac mass (heart weight and myocardial protein content). Ramipril, but not nifedipine or dihydralazine, prevented the development and induced complete regression of cardiac hypertrophy in rats with aortic banding, even at nonantihypertensive doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: